Clinical Trial of Allogeneic Mesenchymal Stem Cell Therapy for Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients Unresponsive to Rituximab and Intravenous Immunoglobulin

Figure 7

Comparison of Th1, Th2, Th17, and Treg subpopulations in the CD4+ T cell population before and after MSC treatment. PBMCs were stained with anti-CD4 PE-Cy7-conjugated, anti-CD25 APC-conjugated, anti-IFN-γ FITC-conjugated, anti-IL-17 PE-conjugated, anti-IL-4 APC-conjugated, anti-CD161 FITC-conjugated, and anti-Foxp3 FITC-conjugated antibodies. CD4+ T cells were gated for further analysis. The proportions (%) of IFN-γ+/CD4+ T cells, IL-17+/CD4+ T cells, IL-4+/CD4+ T cells, IL-17 + CD161+/CD4+ T cells, CD127lowCD25high/CD4+ T cells, and CD25 + FOXP3+/CD4+ T cells in each patient were determined. “Before” indicates the results at the start of MSC treatment, and “After” indicates the results at 3 months after the final MSC infusion. MSCs: mesenchymal stem cells; PBMCs: peripheral blood mononuclear cells.